Adamis Pharmaceuticals (NASDAQ:ADMP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) in a report released on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Stock Down 1.8 %

NASDAQ ADMP opened at $0.37 on Friday. The company has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.51. Adamis Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $1.48.

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) last posted its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $3.81 million. On average, research analysts expect that Adamis Pharmaceuticals will post -0.15 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adamis Pharmaceuticals stock. Capital CS Group LLC bought a new position in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMPGet Rating) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 70,513 shares of the specialty pharmaceutical company’s stock, valued at approximately $40,000. 9.52% of the stock is currently owned by institutional investors and hedge funds.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

Featured Articles

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.